<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018862</url>
  </required_header>
  <id_info>
    <org_study_id>MP441</org_study_id>
    <nct_id>NCT01018862</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 (0.15% Solution) and MP03-33 (0.10% Solution) in Children Ages &gt;6 to &lt;12 With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of an Investigational use of an
      allergy medication (MP03-33) used to treat perennial allergic rhinitis (PAR) to placebo (a
      nasal spray that contains no medicine). In addition, the study will also compare the safety
      and effectiveness of an investigational use of another allergy medication (MP03-36) used to
      treat perennial allergic rhinitis to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      in Children Ages &gt;6 to &lt;12 with Perennial Allergic Rhinitis (PAR)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) for the Entire 28-day Study Period Compared to Placebo</measure>
    <time_frame>baseline to 28 Days</time_frame>
    <description>Change from baseline in 12-hour reflective total nasal symptom score (TNSS) for the entire 28-day study period compared to placebo,scored on a 0 to 24 scale with 0 being no symptoms and 24 being severe symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Instantaneous Total Nasal Symptoms Score (TNSS) for the Entire 28-day Study Period Compared to Placebo</measure>
    <time_frame>baseline to 28 days</time_frame>
    <description>change from baseline in 12-hour instantaneous total nasal symptom score (TNSS) for the entire 28-day study period compared to placebo,scored on a 0 to 24 scale with 0 being no symptoms and 24 being severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 12-hour Reflective Total Ocular Symptoms Score (TOSS) and Instantaneous Total Ocular Symptoms Score (TOSS) for the Entire 28-day Study Period Compared to Placebo</measure>
    <time_frame>baseline to 28 days</time_frame>
    <description>change from baseline in 12-hour instantaneous total ocular symptom score (TOSS) for the entire 28-day study period compared to placebo,scored on a 0 to 18 scale with 0 being no symptoms and 18 being severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Visit 4 in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Compared to Placebo</measure>
    <time_frame>baseline to 28 Days</time_frame>
    <description>change from baseline in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) compared to placebo for the entire 28-day study period compared to placebo,scored on a 0 to 42 scale with 0 being not troubled at all and 42 being extremely troublesome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">489</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>MP03-36 (0.15% solution)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP03-33 (0.10% solution)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelastine hydrochloride nasal spray 0.15%</intervention_name>
    <description>822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
    <arm_group_label>MP03-36 (0.15% solution)</arm_group_label>
    <other_name>Astepro 0.15%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelastine hydrochloride nasal spray 0.10%</intervention_name>
    <description>548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
    <arm_group_label>MP03-33 (0.10% solution)</arm_group_label>
    <other_name>Astepro 0.10%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects &gt;6-&lt;12, inclusive at the screening visit

          -  At least a 1-year history of PAR

          -  The parent must provide written informed consent and the child must provide written
             assent.

          -  Willing and able to comply with the study requirements

          -  The presence of immunoglobulin E (IgE)-mediated hypersensitivity to dust mite,
             cockroach, mold, cat or dog dander, confirmed by a positive response to skin prick
             testing at the Visit 1. A positive response is defined as a wheal diameter of ≥5 mm
             larger than the negative control for the skin prick test. Histamine control must also
             be positive with a wheal diameter &gt;5 mm larger than the control. If there are
             prevailing seasonal allergies, the subject must have a negative skin test to the
             specific allergen.

          -  Screening Visit: Have a 12-hour reflective TNSS of at least 6 out of a possible 12 and
             a congestion score of ≥2 or a rhinorrhea score of ≥2 on Visit 1

          -  Randomization Visit: to be eligible for entry into the double-blind treatment period,
             subjects/caregivers must record:

               1. at least 3 symptom assessments (either AM or PM score) during the past 3 days of
                  the Lead-In Period or the Day of Randomization:

                    1. a 12-hour reflective TNSS ≥ 6

                    2. a 12-hour reflective congestion score of ≥2 or a rhinorrhea score of ≥2

               2. the total of the seven Lead-In symptom assessments during the past 3 days of the
                  Lead-In Period including the Day of Randomization (Visit 2/Day 1):

                    1. a 12-hour reflective TNSS ≥ 42

                    2. a 12-hour reflective congestion score of ≥14 or a rhinorrhea score of ≥14

          -  Must have taken at least 10 doses of study medication during the placebo Lead-In
             Period

          -  General good health and free of any disease or concomitant treatment that could
             interfere with the interpretation of the study results as determined by the
             investigator or the sponsor's medical officer

          -  Subjects receiving immunotherapy injections (antigen desensitization) must be on a
             stable maintenance regimen for at least 30 days before the first study visit
             (adjustments to regimen following a brief period of missed injections do not preclude
             participation). Subjects receiving sublingual immunotherapy are excluded. A 6 month
             washout period is required following the last dose of sublingual immunotherapy.

        Exclusion Criteria:

          -  On nasal examination, subjects with superficial nasal mucosal erosion, moderate nasal
             mucosal erosion, nasal mucosal ulceration, nasal septum perforation (Grade 1B - 4)
             (see section 8.1.4).

          -  Other nasal disease(s) likely to affect deposition of intranasal medication, such as
             acute sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal
             structural abnormalities.

          -  Nasal surgery or sinus surgery within the previous year.

          -  Chronic sinusitis

          -  The use of any investigational drug within 30 days prior to Visit 1. No
             investigational products are permitted for use during the conduct of this study

          -  Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol
             or sucralose (Splenda® brand sweetener)

          -  Females who are pregnant or nursing

          -  Females of childbearing potential who are not abstinent and not practicing a medically
             acceptable method of contraception

          -  Respiratory tract infections within two weeks prior to Visit 1

          -  Subjects with significant pulmonary disease including asthma. Subjects with
             intermittent asthma who only require short-acting inhaled bronchodilators are eligible
             for enrollment.

          -  Chronic obstructive sleep apnea syndrome (clinical diagnosis)

          -  Existence of any surgical or medical condition, which in the opinion of the
             investigator or sponsor's medical monitor, might significantly alter the absorption,
             distribution, metabolism, or excretion of study drug or that might significantly
             affect the subject's ability to complete this trial.

          -  Clinically relevant abnormal physical findings within 1 week of randomization which,
             in the opinion of the investigator, would interfere with the objectives of the study
             or that may preclude compliance with the study procedures

          -  Overnight absences from home for more than 3 nights

          -  Family members of research center or private practice personnel who are directly
             involved in this study are excluded

          -  Members of the same family cannot enroll in the study at the same time

          -  Subjects who have used the medications or therapies that could interfere with symptom
             evaluation within the time period specified (see Section 4.0).

          -  Any behavioral condition which could affect subject's ability to accurately report
             symptoms to the caregiver such as developmental delay, attention deficit disorder, and
             autism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ginsberg, DO</last_name>
    <role>Study Director</role>
    <affiliation>Meda Phamaceuticals, Sr.Dir Medical and Scientific Affairs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma and Respiratory Care Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joann Blessing-Moore,MD</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Allergy and Respiratory Disease Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Medical Group and Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of Santa Clara Valley Research Cntr</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bensch Research Associates</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy and Asthma Centers, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Allergy, Asthma and Immunology</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Allergy</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze and Itch Associates</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Clinical Research, Inc</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine Research Institute of Michigan</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Center, PC</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Center for Clinical Research</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma, Sinus &amp; Allergy Centers, LLC</name>
      <address>
        <city>Warren</city>
        <state>New Jersey</state>
        <zip>07059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Medical Research</name>
      <address>
        <city>Rockville Center</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Center for Clinical Research</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma &amp; Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Institute of Allergy and Asthma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baker Asthma, Allergy and Dermatology Research Center, LLC</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associated Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Consultants of NJ-PA, P.C</name>
      <address>
        <city>Collegeville</city>
        <state>Pennsylvania</state>
        <zip>19426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Consultants, LLP</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isis Clinical Research, LLC</name>
      <address>
        <city>Ausitn</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sirius Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research &amp; Consulting Inc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Sky Medical Research</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Clinical Research</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marycliff Allergy Specialists</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gary Steven, MD</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <results_first_submitted>March 22, 2012</results_first_submitted>
  <results_first_submitted_qc>May 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2012</results_first_posted>
  <last_update_submitted>May 10, 2012</last_update_submitted>
  <last_update_submitted_qc>May 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MP03-36 (0.15% Solution)</title>
          <description>822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>MP03-33 (0.10% Solution)</title>
          <description>548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MP03-36 (0.15% Solution)</title>
          <description>822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>MP03-33 (0.10% Solution)</title>
          <description>548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="162"/>
            <count group_id="B4" value="489"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8" spread="2.6"/>
                    <measurement group_id="B2" value="8.8" spread="2.7"/>
                    <measurement group_id="B3" value="8.7" spread="2.8"/>
                    <measurement group_id="B4" value="8.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) for the Entire 28-day Study Period Compared to Placebo</title>
        <description>Change from baseline in 12-hour reflective total nasal symptom score (TNSS) for the entire 28-day study period compared to placebo,scored on a 0 to 24 scale with 0 being no symptoms and 24 being severe symptoms.</description>
        <time_frame>baseline to 28 Days</time_frame>
        <population>participant must have had at least one post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>MP03-36 (0.15% Solution)</title>
            <description>822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MP03-33 (0.10% Solution)</title>
            <description>548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) for the Entire 28-day Study Period Compared to Placebo</title>
          <description>Change from baseline in 12-hour reflective total nasal symptom score (TNSS) for the entire 28-day study period compared to placebo,scored on a 0 to 24 scale with 0 being no symptoms and 24 being severe symptoms.</description>
          <population>participant must have had at least one post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.45" spread="4.03"/>
                    <measurement group_id="O2" value="-3.37" spread="4.37"/>
                    <measurement group_id="O3" value="-2.48" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Instantaneous Total Nasal Symptoms Score (TNSS) for the Entire 28-day Study Period Compared to Placebo</title>
        <description>change from baseline in 12-hour instantaneous total nasal symptom score (TNSS) for the entire 28-day study period compared to placebo,scored on a 0 to 24 scale with 0 being no symptoms and 24 being severe symptoms.</description>
        <time_frame>baseline to 28 days</time_frame>
        <population>participant must have had at least one post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>MP03-36 (0.15% Solution)</title>
            <description>822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MP03-33 (0.10% Solution)</title>
            <description>548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Instantaneous Total Nasal Symptoms Score (TNSS) for the Entire 28-day Study Period Compared to Placebo</title>
          <description>change from baseline in 12-hour instantaneous total nasal symptom score (TNSS) for the entire 28-day study period compared to placebo,scored on a 0 to 24 scale with 0 being no symptoms and 24 being severe symptoms.</description>
          <population>participant must have had at least one post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.70" spread="3.91"/>
                    <measurement group_id="O2" value="-3.00" spread="4.42"/>
                    <measurement group_id="O3" value="-2.38" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 12-hour Reflective Total Ocular Symptoms Score (TOSS) and Instantaneous Total Ocular Symptoms Score (TOSS) for the Entire 28-day Study Period Compared to Placebo</title>
        <description>change from baseline in 12-hour instantaneous total ocular symptom score (TOSS) for the entire 28-day study period compared to placebo,scored on a 0 to 18 scale with 0 being no symptoms and 18 being severe symptoms.</description>
        <time_frame>baseline to 28 days</time_frame>
        <population>participant must have had at least one post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>MP03-36 (0.15% Solution)</title>
            <description>822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MP03-33 (0.10% Solution)</title>
            <description>548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 12-hour Reflective Total Ocular Symptoms Score (TOSS) and Instantaneous Total Ocular Symptoms Score (TOSS) for the Entire 28-day Study Period Compared to Placebo</title>
          <description>change from baseline in 12-hour instantaneous total ocular symptom score (TOSS) for the entire 28-day study period compared to placebo,scored on a 0 to 18 scale with 0 being no symptoms and 18 being severe symptoms.</description>
          <population>participant must have had at least one post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="2.72"/>
                    <measurement group_id="O2" value="-1.51" spread="3.12"/>
                    <measurement group_id="O3" value="-1.28" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Visit 4 in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Compared to Placebo</title>
        <description>change from baseline in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) compared to placebo for the entire 28-day study period compared to placebo,scored on a 0 to 42 scale with 0 being not troubled at all and 42 being extremely troublesome.</description>
        <time_frame>baseline to 28 Days</time_frame>
        <population>participant must have had at least one post baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>MP03-36 (0.15% Solution)</title>
            <description>822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>MP03-33 (0.10% Solution)</title>
            <description>548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Visit 4 in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Compared to Placebo</title>
          <description>change from baseline in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) compared to placebo for the entire 28-day study period compared to placebo,scored on a 0 to 42 scale with 0 being not troubled at all and 42 being extremely troublesome.</description>
          <population>participant must have had at least one post baseline efficacy assessment</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.95"/>
                    <measurement group_id="O2" value="-0.38" spread="0.87"/>
                    <measurement group_id="O3" value="-0.38" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MP03-36 (0.15% Solution)</title>
          <description>822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>MP03-33 (0.10% Solution)</title>
          <description>548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>medra</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>uri</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>nasopharynigitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>pharyngitis streptoccal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>nasal discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>sneezing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr.Director Medical Scientific Affairs</name_or_title>
      <organization>Meda Pharmaceuticals Inc</organization>
      <phone>732 564 2200</phone>
      <email>David.ginsberg@meda.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

